At the EULAR 2022 Congress in Copenhagen, Denmark, two experts debated whether COVID-19 will have a lasting effect on rheumatology clinical practice.

An analysis of data from the COVID-19 Global Rheumatology Alliance and EULAR COVID-19 registries suggests high rates of severe COVID-19 among people with primary systemic vasculitis or polymyalgia rheumatica.

Findings from two real-world studies presented at the EULAR 2021 Virtual Congress suggest that JAK inhibitors and biologics are similarly effective for the treatment of inflammatory arthritis.

The study, which was presented at the EULAR 2021 Virtual congress and published in the Annals of the Rheumatic Diseases , included 2869 RA patients (mean age 57 years, 81% women) treated with biologics or targeted synthetic DMARDs at the time of COVID-19 onset who were entered into the C19-GRA registry between March 2020 and April 2021.

EULAR 2021 Virtual Congress; 2–5 June

Serious infections were reported in 13.3% and 15.2% of patients, respectively, and a corresponding 66.3% and 80.5% had AEs judged by the investigators to be potentially related to glucocorticoids. m edwireNews is an independent medical news service provided by Springer Healthcare. © 2020 Springer Healthcare part of the Springer Nature Group EULAR 2020 E-Congress; 3–6 Jun Ann Rheum Dis 2020; doi:10.1136/annrheumdis-2020-eular.1073

“The Great Debate” of the ACR Convergence 2020 virtual meeting addressed the question of whether JAK inhibitors should be given before biologics following an inadequate response to methotrexate in patients with rheumatoid arthritis.

There were a variety of sessions at the EULAR 2020 E-Congress talking about the risk factors associated with COVID-19 hospitalization among patients with rheumatic conditions, as data from the COVID-19 Global Rheumatology Alliance registry and contributing national registries become available.

There were no serious adverse events in the secukinumab group, and two in the placebo arm. medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2020 Springer Healthcare Ltd, part of the Springer Nature Group ACR Convergence virtual meeting; 5–9 November 2020

EULAR 2020: Pedro Machado discusses COVID-19 Global Rheumatology Alliance registry data on risk factors for COVID-19 hospitalization in rheumatic

Conversely, patients aged 65 years and older had an almost threefold higher risk for VTEs than younger patients, and those with C-reactive protein (CRP) levels of 5 mg/L or higher had an approximately twofold increased risk versus individuals with lower CRP levels. m edwireNews is an independent medical news service provided by Springer Healthcare. © 2020 Springer Healthcare part of the Springer Nature Group EULAR 2020 E-Congress; 3–6 June Ann Rheum Dis 2020; doi:10.1136/annrheumdis-2020-eular.1505 Anja Strangfeld_040620

m edwireNews is an independent medical news service provided by Springer Healthcare. © 2020 Springer Healthcare part of the Springer Nature Group EULAR 2020 E-Congress; 3–6 June Ann Rheum Dis 2020; doi:10.1136/annrheumdis-2020-eular.353 John Isaacs_060620

EULAR 2020: John Isaacs comments on two studies on venous thromboembolism in patients with rheumatoid arthritis. 

EULAR 2020: Anja Strangfeld discusses German RABBIT registry analysis comparing venous thromboembolism risk in rheumatoid arthritis.

EULAR has released provisional recommendations for the management of rheumatic diseases during the COVID-19 pandemic.

Fernando Pérez-Ruiz discusses some of the key gout and crystal arthritis studies presented at the EULAR 2020 E-Congress (8:10).

Oliver FitzGerald outlines his highlights from the psoriatic arthritis presentations at the EULAR 2020 E-Congress, and discusses what the study results mean for clinical practice (10:13).

The SELECT-PsA-1 and SELECT-PsA-2 trials presented at the EULAR 2020 E-Congress have demonstrated that upadacitinib may be a promising treatment option for psoriatic arthritis patients with and without prior exposure to biologic agents.

Osteoscan, an artificial intelligence program, determines the radiographic stage of knee osteoarthritis with 95% accuracy, indicate findings from the EULAR 2020 E-Congress.

Methotrexate treatment does not contribute to the increased risk for interstitial lung disease observed among patients with rheumatoid arthritis, according to data from a Danish cohort study presented at the EULAR 2020 E-congress.